Ranferon-12 tonic mitigates haematological abnormalities in cyclophosphamide-treated rat
Ranferon-12 tonic mitigate haematotoxicity in CPA-treated rat
DOI:
https://doi.org/10.4314/njbmb.v39i1.3Keywords:
Ranferon-12 tonic, Cyclophosphamide, haematological abnormalities, oxidative stress, haematopoietic factor, haematopoiesis.Abstract
Cyclophosphamide (CPA) is a well-known anticancer drug despite its toxicity including haematotoxicity. Ranferon-12 tonic (RFT), constitute important ingredients for blood building. This study investigated the mitigation potential of RFT on haematotoxicity in CPA-treated rat. Twenty-four rats were assigned to four groups (n=6). Group A: (Control) received 0.4 mL of normal-saline (NS) orally for 7 days. Group B: (CPA) received 0.4 mL of NS orally for 7 days and single injection of CPA (200 mg/kg) intraperitoneally (i.p.) on the 7th day. Groups C: (RFT) and D: (RFT+CPA) received RFT at 0.029 mL/kg orally for 7 days and the latter (i.e. Group D) followed by single injection of CPA (200 mg/kg) i.p. on the 7th day. Twenty-four hours after the last treatment (i.e. on Day 8), the rats were weighed and sacrificed under anaesthesia. Blood was collected via cardiac puncture and transferred to EDTA and plain tubes for further analysis. A single CPA-injection (200 mg/kg/rat), after 24 h, caused significant (p < 0.05) decrease in RBC, Hb, PCV, WBC and PLT (values >36%). Also, there was a significantly (p<0.05) increase in the body temperature by 5.1 %. Furthermore, decreased levels of SOD and CAT with a concomitant rise in MDA content were observed. All these alterations were mitigated; to some extent, in animals pre-treated with RFT prior to CPA-injected. The data suggest that RFT could mitigate haematotoxicity in CPA-treated rat by suppressing inflammation/oxidative stress via modulation of haematopoietic factors, and in turn promote haematopoietic stem cells as well as haematopoiesis.
Downloads
References
Bills, N. D., Koury, M. J, Clifford, A. J. and Dessypris, E. N. (1992). Ineffective
hematopoiesis in folate-deficient mice. Blood, 79(9):2273-2280.
Blatteis, C. M. (2000). The afferent signalling of fever. The Journal of Physiology, 526:470-
Buege, J. A. and Aust, S. D. (1978). Microsomal lipid peroxidation. Methods in Enzymology,
:302-310.
Colvin, O. M. (1999). An overview of cyclophosphamide development and clinical
applications. Current Pharmaceutical Design, 5:555-560.
El-Naggar, S. A., Alm-Eldeen, A. A., Germoush, M. O., El-Boray, K.F. and Elgebaly, H.A.
(2015) Ameliorative effect of propolis against cyclophosphamide-induced toxicity in mice. Pharmaceutical Biology, 53(2):235-241.
Fan, C. M., Su, Y. W., Howe, P. R. and Xian, C. J. (2018). Long chain omega-3
polyunsaturated fatty acid supplementation protects against adriamycin and cyclophosphamide chemotherapy-induced bone marrow damage in female rats. International Journal of Molecular Sciences, 19(2):484.
Ferguson, L. R. and Pearson, A. E. (1996). The clinical use of mutagenic anticancer drugs.
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 355(12):1-12.
Fraiser, L. H., Kanekal, S. and Kehrer, J. P. (1991). Cyclophosphamide toxicity:
characterising and avoiding the problem. Drugs, 42:781-795.
Haiden, N., Klebermass, K., Cardona, F., Schwindt, J., Berger, A. and Kohlhauser-Vollmuth,
C. (2006). A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics, 118(1):180-188.
Hoffman, R, Benz Jr, E. J., Silberstein, L. E., Heslop, H., Anastasi, J. and Weitz, J. (2013).
Hematology: basic principles and practice. Elsevier Health Sciences, 2013.
Iqubal, A., Syed, M. A., Haque, M. M., Najmi, A. K., Ali, J. and Haque, S. E. (2020). Effect
of nerolidol on cyclophosphamide-induced bone marrow and hematologic toxicity in Swiss albino mice. Experimental Hematology, 82:24-32.
Kameo, S. Y, Ramos, M. J. O., Lima, R. B., Amorim, B. F., dos Santos, J. C., Marinho, P. M.
L., Sawada, N. O. and Silva, G. M. (2021). Hematotoxicity and functional impacts related to chemotherapy with doxorubicin and cyclophosphamide for invasive ductal breast carcinoma: a study in clinical records. Journal of Health and Biological Sciences, 9(1):1-8.
Kehrer, J. P. and Biswal, S. S. (2000). The molecular effects of acrolein. Toxicological
Sciences, 57(1):6-15.
Koury, M. J. and Ponka, P. (2004). New insights into erythropoiesis: the roles of folate,
vitamin B12, and iron. Annual Review of Nutrition, 24:105-131.
Lakshmi, C., Deb, C., Ray, C. and Ray, M. R. (2005). Reduction of hematotoxicity and
augmentation of antitumor efficacy of cyclophosphamide by dopamine. Neoplasma, 52(1):68-73.
Liu, M., Li, P., Zeng, X., Wu, H., Su, W. and He, J. (2015). Identification and
pharmacokinetics of multiple potential bioactive constituents after oral administration of radix astragali on cyclophosphamide-induced immunosuppression in Balb/c mice. International Journal of Molecular Sciences, 16(3):5047-5071.
Liu, M., Tan, H., Zhang, X., Liu, Z., Cheng, Y. and Wang, D. (2014). Hematopoietic effects
and mechanisms of Fufang E׳ jiao Jiang on radiotherapy and chemotherapy-induced myelosuppressed mice. Journal of Ethnopharmacology, 152(3):575-584.
Martin, P., Dailey, M. and Sugarman, E. (1987). Negative and positive assays of superoxide
dismutase based on haematoxylin autoxidation. Archives of Biochemistry and Biophysics, 255:329-336.
Mitra, S., Paul, S., Roy, S., Sutradhar, H., Bin Emran, T. and Nainu, F. (2022). Exploring the
immune-boosting functions of vitamins and minerals as nutritional food bioactive compounds: a comprehensive review. Molecules, 27(2):555.
Patra, K., Bose, S., Sarkar, S., Rakshit, J, Jana, S, Mukherjee, A., Roy, A., Mandal, D. P. and
Bhattacharjee, S. (2012). Amelioration of cyclophosphamide induced myelosuppression and oxidative stress by cinnamic acid. Chemico-biological Interactions, 195(3):231-239.
Peng, X., Zhang, X., Wang, C. and Olatunji, O. J. (2022). Protective effects of asperuloside
against cyclophosphamide-induced urotoxicity and hematotoxicity in rats. Open Chemistry, 20(1):1444-1450.
Pizzo, P. A. (1999). Fever in immunocompromised patients. New England Journal of
Medicine, 341(12):893-900.
Remacha, A. F., Wright, I., Fernández‐Jiménez, M. C., Toxqui, L., Blanco‐Rojo, R., Moreno,
G. and Vaquero, M. P. (2015). Vitamin B12 and folate levels increase during treatment of iron deficiency anaemia in young adult woman. International Journal of Laboratory Hematology, 37(5):641-648.
Sinha, A. K. (1972). Colorimetric assay of catalase. Analytical Biochemistry, 47:389-394.
Testart-Paillet, D., Girard, P., You, B., Freyer, G., Pobel, C. and Tranchand, B. (2007).
Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Critical Reviews in Oncology/Hematology, 63(1):1-11.
Tian, J. S., Zhao, H. L., Gao, Y., Wang, Q., Xiang, H. and Xu, X. P. (2021). Branched-Chain
Amino Acids Catabolism Pathway Regulation Plays a Critical Role in the Improvement of Leukopenia Induced by Cyclophosphamide in 4T1 Tumor-Bearing Mice Treated with Lvjiaobuxue Granule. Frontiers in Pharmacology, 12:657047.
Ukpo, G. E., Ehianeta, T. S., Adegoke, A. Y. and Salako, O. A. (2013). Evaluation of the
haematological and biochemical effects of Averon®. A herbal formulation, against cyclophosphamide-induced immunomodulated male rats. International Journal of Pharmaceutical Sciences and Research, 4(9):3556.
Wang, H., Wang, M., Chen, J., Tang, Y., Dou, J., Yu, J., Xi, T. and Zhou, C. (2011). A
polysaccharide from Strongylocentrotus nudus eggs protects against myelosuppression and immunosuppression in cyclophosphamide-treated mice. International Immunopharmacology, 11(11):1946-1953.
Additional Files
Published
License
Copyright (c) 2024 Dr. Okafor Azubuike
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
